Summit Partners Public Asset Management, LLC Ascendis Pharma A/S Transaction History
Summit Partners Public Asset Management, LLC
- $2.79 Billion
- Q3 2024
A detailed history of Summit Partners Public Asset Management, LLC transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Summit Partners Public Asset Management, LLC holds 55,101 shares of ASND stock, worth $7.36 Million. This represents 0.3% of its overall portfolio holdings.
Number of Shares
55,101
Previous 130,700
57.84%
Holding current value
$7.36 Million
Previous $17.8 Million
53.84%
% of portfolio
0.3%
Previous 0.78%
Shares
7 transactions
Others Institutions Holding ASND
# of Institutions
244Shares Held
58.8MCall Options Held
250KPut Options Held
377K-
Ra Capital Management, L.P. Boston, MA9.71MShares$1.3 Billion20.22% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.13MShares$685 Million3.62% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.99MShares$666 Million11.21% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.41MShares$589 Million1.03% of portfolio
-
Janus Henderson Group PLC London, X04.19MShares$559 Million0.33% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $7.45B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...